| |
[All], N = 120
|
Number
|
|---|
|
Age
|
61 [54.7; 65.4]
|
120
|
|
< 65
|
91 (75.8%)
|
|
> 65
|
29 (24.2%)
|
|
Sex
|
120
|
|
F
|
22 (18.3%)
|
|
M
|
98 (81.7%)
|
|
Disease
|
|
ALD
|
75 (62.5%)
|
|
HCV
|
14 (11.7%)
|
|
HBV
|
7 (5.8%)
|
|
Cryptogen
|
12 (10%)
|
|
Other
|
12 (10%)
|
|
AFP (ng/ml)
|
8.00 [4.10; 70.0]
|
105
|
|
Waiting_time (days)
|
212 [72.5; 347]
|
120
|
|
D (mm)
|
33.2 (20.8)
|
120
|
|
MELD
|
11 [8; 15]
|
97
|
|
MELD ≤ 15
|
71 (73.2%)
|
|
MELD = 15–30
|
17 (17.5%)
|
|
MELD > 30
|
9 (9.28%)
|
|
preTreat
|
120
|
|
No pre-treatment
|
45 (37.5%)
|
|
Pre-treatment
|
75 (62.5%)
|
|
N
|
100
|
|
N = 1
|
59 (59.0%)
|
|
N = 1–3
|
30 (30.0%)
|
|
N > 3
|
11 (11.0%)
|
|
Grade
|
59
|
|
1
|
23 (39.0%)
|
|
2
|
33 (55.9%)
|
|
3
|
3 (5.08%)
|
|
Asan
|
120
|
|
Exceeding
|
35 (29.2%)
|
|
Fulfilling
|
85 (70.8%)
|
|
AFP score
|
105*
|
|
> 2
|
26 (24.8%)
|
|
≤ 2
|
79 (75.2%)
|
|
MC
|
120
|
|
Exceeding
|
46 (38.3%)
|
|
Fulfilling
|
74 (61.7%)
|
|
UTS
|
120
|
|
Exceeding
|
34 (28.3%)
|
|
Fulfilling
|
86 (71.7%)
|
- ALD alcoholic liver disease, HCV hepatitis C virus, HBV hepatitis B virus, AFP alpha-feto protein in ng/ml, D diameter of the largest tumor in mm, MELD model of end-stage liver disease, N number of tumors, MC Milan criteria, UTS up-to-seven criteria
- *Missing AFP values for 15 patients. Data are shown as the average and standard deviation (round brackets) for normally distributed data and as the median and quantiles (square brackets) for non-normally distributed data
